Parathyroid Hormone (1-34) (human) (trifluoroacetate salt)

Formulation: A lyophilized powder

Formal Name: L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-methionyl-L-histidyl-L-asparaginyl-L-leucylglycyl-L-lysyl-L-histidyl-L-leucyl-L-asparaginyl-L-seryl-L-methionyl-L-α-glutamyl-L-arginyl-L-valyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-arginyl-L-lysyl-L-lysyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-valyl-L-histidyl-L-asparaginyl-L-phenylalanine, trifluoroacetate salt

Purity: ≥95%

Formula Markup: C181H291N55O51S2 • XCF3COOH

Formula Weight: 4117,7

Shelf life (days): 1460

Notes: Parathyroid hormone (PTH) (1-34) is an N-terminal fragment of PTH that regulates bone remodeling.{41734} It is a PTH receptor agonist that binds to the PTH1 receptor (IC50 = 2 nM) and increases cAMP accumulation (IC50 = 0.22 pM) in HEK293 cells expressing human PTH1.{41735} PTH (1-34) also stimulates cAMP accumulation in Saos-2 human osteoblast-like cells (IC50 = 0.38 nM) and bone resorption from neonatal mouse calvariae in vitro. In vivo, PTH (1-34) (40 µg/kg per day) increases bone mass in an ovariectomized adult rat model of postmenopausal osteoporosis.{41736} It also increases proteoglycan content and inhibits articular cartilage degeneration in knee joints in a mouse model of injury-induced osteoarthritis when administered at a dose of 40 µg/kg per day immediately following injury.{41737} Formulations containing PTH (1-34) have been used in the treatment of osteoporosis in men and postmenopausal women who are at high risk for fracture.

• Artikelnummer: CAY24985
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 24985-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK